Curaleaf (OTCMKTS:CURLF – Get Free Report) issued its quarterly earnings results on Wednesday. The company reported $0.05 earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.25, Zacks reports. Curaleaf had a negative return on equity of 8.11% and a negative net margin of 7.76%.
Curaleaf Stock Down 7.3%
Shares of CURLF traded down $0.66 on Wednesday, hitting $8.35. 153,036 shares of the stock traded hands, compared to its average volume of 314,353. Curaleaf has a one year low of $4.56 and a one year high of $15.15. The company has a market capitalization of $1.95 billion, a PE ratio of -21.41 and a beta of 1.56. The business has a 50 day simple moving average of $7.07 and a 200 day simple moving average of $7.68. The company has a debt-to-equity ratio of 1.05, a quick ratio of 0.74 and a current ratio of 1.56.
Wall Street Analysts Forecast Growth
Separately, Zacks Research raised shares of Curaleaf from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 14th. Three research analysts have rated the stock with a Strong Buy rating and one has issued a Buy rating to the company. According to data from MarketBeat, Curaleaf presently has an average rating of “Strong Buy”.
About Curaleaf
Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.
Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.
Further Reading
- Five stocks we like better than Curaleaf
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
- Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
Receive News & Ratings for Curaleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curaleaf and related companies with MarketBeat.com's FREE daily email newsletter.
